You are here: Industry Insights > cenobamate

News List

Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy pharmatimes
February 09, 2022
Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy.
Ontozry Receives Positive CHMP Opinion Treatment of Uncontrolled Focal Onset Seizures americanpharmaceuticalreview
February 04, 2021
Arvelle Therapeutics announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the adjunctive treatment of focal onset seizures with or without secondary ...
Angelini Pharma acquires Arvelle Therapeutics for $960 million expresspharma
January 05, 2021
Angelini Pharma will have the exclusive license to commercialise cenobamate in the European Union and other countries in the European Economic Area.
SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan prnasia
October 15, 2020
SK Biopharmaceuticals and Ono Pharmaceutical announced that they have entered into an exclusive licensing agreement for Ono to develop and commercialize cenobamate in Japan.
EMA accepts marketing authorisation application for anti-epileptic drug cenobamate europeanpharmaceuticalreview
April 03, 2020
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
FDA Approves XCOPRI for Partial-Onset Seizures in Adult Patients americanpharmaceuticalreview
December 17, 2019
The U.S. Food and Drug Administration (FDA) approved XCOPRI (cenobamate) for the treatment of partial-onset seizures in adult patients.
SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe pharmaceutical-technology
February 15, 2019
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe....